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Abstract
Background—The drug overdose mortality rate tripled between 1990 and 2006; prescription 
opioids have driven this epidemic. We examined the period 1990–2006 to inform our 
understanding of how the current prescription opioid overdose epidemic emerged in urban areas.
Methods—We used data from the Office of the Chief Medical Examiner to examine changes in 
demographic and spatial patterns in overdose fatalities induced by prescription opioids (i.e., 
analgesics and methadone) in New York City (NYC) in 1990–2006, and what factors were 
associated with death from prescription opioids vs. heroin, historically the most prevalent form of 
opioid overdose in urban areas.
Results—Analgesic-induced overdose fatalities were the only types of overdose fatalities to 
increase in 1990–2006 in NYC; the fatality rate increased sevenfold from 0.39 in 1990 to 2.7 per 
100,000 persons in 2006. Whites and Latinos were the only racial/ethnic groups to exhibit an 
increase in overdose-related mortality. Relative to heroin overdose decedents, analgesic and 
methadone overdose decedents were more likely to be female and to concurrently use 
psychotherapeutic drugs, but less likely to concurrently use alcohol or cocaine. Analgesic 
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overdose decedents were less likely to be Black or Hispanic, while methadone overdose decedents 
were more likely to be Black or Hispanic in contrast to heroin overdose decedents.
Conclusions—The distinct epidemiologic profiles exhibited by analgesic and methadone 
overdose fatalities highlight the need to define drug-specific public health prevention efforts.
Keywords
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1. Introduction
Overdose death linked to prescription opioids is a growing public health crisis. The current 
epidemic accelerated during a fifteen-year interval between 1990 and 2006. In particular, the 
mortality rate from drug overdose tripled between 1990 and 2006 (CDC, 2010): by 2006, the 
number of overdose deaths in the United States exceeded the number of suicides; by 2009, 
they also exceeded the number of motor vehicle deaths. Prescription opioid analgesics, 
painkillers derived from opium or synthesized to possess narcotic properties similar to 
opioids, including oxycodone, hydrocodone and codeine, have driven this overdose 
epidemic (CDC, 2011; Warner et al., 2009). Prescription opioids may have been obtained 
legally through a prescription, or diverted through illegal distribution networks.
Although much has been written about the epidemic of prescription drug use in rural areas 
(Green et al., 2011; Hall et al., 2008; Paulozzi et al, 2009; Piercenfield et al., 2010; Shah et 
al, 2008; Wunsch et al, 2009), the epidemic increase in prescription opioid overdose that 
occurred between 1990 and 2006 is also reflected in urban areas. For example, from 1997 to 
2002, the number of overdose deaths involving prescription opioids increased 97% in 
metropolitan areas during a time when overdose from all drugs increased only 27% 
(Paulozzi, 2006). By 2002, prescription opioids were involved in more deaths than heroin or 
cocaine, the two drugs responsible for most drug abuse in the 1990s (Paulozzi, 2006).
Little information exists on the demographic or spatial patterns of fatal prescription opioid 
overdose in urban areas in the period leading up to the emergence of the epidemic. Urban 
studies have focused on the patterns of prescription opioid misuse at one point in time 
among specific subgroups such as street drug users or marijuana smoking young women 
(Bardhi et al, 2007; Davis and Johnson, 2008; Lankenau et al., 2012a, 2012b), but to our 
knowledge, no study has yet examined the longitudinal trends and geographic variation of 
prescription opioid overdose in a major city in this period.
Therefore, examining the period leading up to the current prescription opioid overdose 
epidemic in urban areas can lead to important insights. Examining such a period can help us 
identify new urban patterns of prescription opioid overdose before they become ubiquitous, 
and can inform our understanding of how future epidemics may emerge.
Studies conducted in primarily rural states, such as the Appalachian, Great Plains and 
Southwest regions (Green et al., 2011; Hall et al., 2008; Paulozzi et al., 2009; Piercenfield et 
al., 2010; Shah et al., 2008; Wunsch et al., 2009) can inform our urban research. The highest 
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increases in fatalities in the period of 1990–2006 occurred among males, persons 35–54 
years old, and non-Hispanic Whites (Green et al., 2011; Hall et al., 2008; Paulozzi et al., 
2009; Piercenfield et al., 2010; Shah et al., 2008; Warner et al., 2009). Geographic variation 
has also been noted, with the largest increases found in rural areas and in areas with high 
retail drug availability (Brownstein et al., 2010; Havens et al., 2007a, 2007b). These secular 
changes have led to the concentration of prescription opioid overdose deaths in the current 
time among non-Hispanic White and American Indian/Alaska Native males in rural, low-
income areas (Paulozzi et al., 2011). A comprehensive examination of the demographic and 
geographic variation in prescription opioid overdose fatalities within a city can be critical to 
help us identify the individual- and contextual-level factors that may be associated with the 
emergence of this problem in urban areas. Further, an understanding of where prescription 
opioid overdoses became concentrated in this period can aid in the deployment of 
surveillance and control efforts.
A critical issue to consider when understanding the emergence of a prescription opioid 
overdose epidemic in urban areas, is how the profile of prescription opioid overdose differs 
from that of other types of drug overdose. Prior studies have shown, for example, that 
prescription opioid overdose decedents are more likely to be older, female, White, and to 
have concurrently used psychotherapeutic drugs than heroin overdose decedents (Green et 
al., 2011; Shah et al., 2008). Given the historical focus of urban drug overdose research and 
prevention efforts on non-prescription drugs, identifying distinctions can facilitate the 
adaptation of current urban drug prevention strategies.
This study aimed to analyze the epidemiology of prescription opioid-related overdose deaths 
in New York City (NYC) in the period leading to the emergence of the epidemic (1990–
2006) by examining longitudinal trends and geographic differences within this city. In 
particular, we examined: (1) changes in the epidemiologic patterns of prescription opioid 
overdose death in NYC in 1990–2006; (2) changes in patterns of spatial variation in 
prescription opioid overdose deaths across NYC neighborhoods in this time period; and (3) 
whether the profile of prescription opioid overdose decedents in NYC differed from the 
profile of heroin overdose decedents, the historically most prevalent form of opioid overdose 
in urban areas (Bryant et al., 2004; Frank, 2000). Prescription opioid overdose fatalities were 
examined as two types: analgesic opioid and methadone-induced overdose. Methadone has 
been prevalent in NYC for decades, and it presents a potentially distinct etiology from 
analgesic overdose (New York City Department of Health and Mental Hygiene, 2011).
2. Methods
2.1. Study population
Cases of fatal unintentional poisoning deaths (ICD-10 codes X40–X44, T40.0–T40.2) 
occurring in adults aged 15–64 years in NYC between 1990 and 2006 were identified 
through manual review of medical files at the Office of the Chief Medical Examiner of NYC 
(OCME) from 1990 to 2006. The OCME is responsible for investigating all deaths of people 
believed to have died from unnatural causes. Thus, all overdose deaths in NYC are reviewed 
by the OCME and would have been included in the charts used for data extraction.
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Decedent’s medical history, the circumstances and environment of the death, autopsy 
findings, and laboratory data were used to attribute the cause of death to each case reviewed. 
Hence, classification of cause of death differs from simple presence or absence of a drug in a 
toxicological screen. Decedents with positive screens for a prescription opioid will not 
necessarily be classified as a prescription opioid-induced death, they may, instead, be 
classified as other types of accidental, non-overdose deaths or intentional deaths. 
Attributions of drugs as a cause of death by the OCME are not mutually exclusive: an 
overdose death may be attributed to more than one drug. Medical Examiner systems have 
shown high sensitivity, specificity and positive predictive value to identify external causes 
of death (Comstock et al., 2005; Landen et al., 2003; Sternfeld et al., 2010). Data regarding 
cause of death, circumstances of death, and toxicology were collected from the OCME files 
by trained abstractors using a standardized protocol and data collection forms. Further 
details on overdose data collection are provided in Galea et al. (2003).
Cases of unintentional overdose death in which a prescription opioid was cited as a cause of 
death, alone or in combination with other drugs, were classified as prescription opioid 
overdose deaths. Prescription opioids were classified as two types: (1) analgesic opioids 
(hereafter referred to as “analgesics”), including codeine, fentanyl, hydrocodone, 
hydromorphone, meperidine, morphine, oxycodone, and propoxyphene (the proportion of 
analgesic drug overdose deaths due to each type of analgesic drug is presented as online 
Supplementary Material1) and (2) methadone. Unintentional deaths with an undetermined 
cause, as well as overdose deaths with an undetermined drug that caused the overdose, were 
not included in the study. Deaths caused by intentional injury are not considered accidents 
by the OCME; hence, overdose deaths due to suicide were not considered in this study. Of 
all opioid-induced deaths, only 0.5% were listed as undetermined or suicide.
2.3. Covariates
To characterize the decedents from prescription opioid overdose, we abstracted the 
following characteristics from the OCME file: decedent sex, age, place of injury, and NYC 
borough of death. We also examined the proportion of prescription opioid overdose deaths 
in which heroin overdose was also a contributing cause, and the proportion of prescription 
opioid overdose deaths with positive toxicology reports for non-opioid substances, including 
alcohol, cannabinoids, cocaine, benzodiazepines, and antidepressants. The latter substances 
were detected but not considered primary causes of death in the cases of prescription opioid 
overdose deaths. A list of the benzodiazepine and antidepressant drugs detected is presented 
as online Supplementary Material.2
2.4. Statistical analyses
To fulfill our first objective of examining changes in epidemiologic patterns of analgesic 
overdose death, we followed three steps. We first compared the evolution of overdoses 
caused by prescription opioids to overdoses caused by other leadings types of drugs. We 
1Supplementary material can be found by accessing the online version of this paper. Please see Appendix A for more information.
2Supplementary material can be found by accessing the online version of this paper. Please see Appendix B for more information.
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calculated the overdose death rate per 100,000 person-years by leading type of drugs (single 
and polydrug-induced overdose by cocaine, heroin, alcohol, methadone and analgesics) for 
each year from 1990 to 2006. To determine the rate denominators, we obtained total, age-, 
sex-, and race/ethnic-specific population counts for New York City for 1990 and 2000 from 
the Census Summary File 3 and for 2005–2006 from the American Community Survey 
(ACS) 2005–2009 (United States Census Bureau, 2012a, 2012b, 2012c). Population counts 
for the intervening years were computed using linear interpolation. We standardized cause-
specific overdose mortality rates for New York City by age, sex, and race to the 2000 census 
for New York City to enable comparability between years in the analysis (Galea et al., 
2003). A non-parametric test of trend across ordered groups was used to assess the 
significance of changes in the rates of drug-specific-induced deaths over time (Cuzick, 
1985).
Second, we examined the evolution of prescription opioid overdose by race/ethnicity and 
sex. We calculated prescription opioid overdose death rates between 1990 and 2006 
stratified by race and sex. We focused on the three largest racial/ethnic groups: White, Black 
and Latino. Thus, we calculated the age-standardized rate of overdose deaths caused by 
analgesics and methadone for White males, White females, Black males, Black females, 
Latino males, and Latino females.
Third, we examined whether the patterns of co-occurring non-opioid drugs detected varied 
over time. In particular, we used a non-parametric test of trend to test whether the proportion 
of analgesic and methadone overdose fatalities with positive toxicology reports for non-
opioid drugs (specifically, alcohol, cannabinoids, cocaine, benzodiazepines, and 
antidepressants) differed over time.
To fulfill our second objective of investigating changes in patterns of spatial variation in 
analgesic overdose deaths, we presented the spatial distribution of prescription opioid 
overdose death rates in 1990–1995, 1996–2000, and 2001–2006 across NYC neighborhoods. 
All OCME analgesic opioid overdose cases in 1990–2006 were geocoded to the 
neighborhood level by address of injury using ArcGIS software, version 9.0 (ESRI, 2011). 
Only cases with a valid address of injury (i.e., 88%) were included in the analysis; these 
cases did not differ in demographic characteristics from cases without a valid address of 
injury.
Neighborhoods consist of adjoining zip codes, designated to approximate New York City 
Community Planning Districts. The assignment of zip code areas to neighborhoods, the 
decisions about which community planning districts were most appropriate to combine, and 
the delineation of neighborhoods were made by the Department of City Planning in 
consultation with local residents. The 59 neighborhood boundaries have remained 
unchanged between the 1990 and 2000 census (New York City Department of City 
Planning, 2012).
Age-adjusted rates were calculated for each year and then averaged for each five-year 
grouping. Small neighborhood-and year-specific cell sizes by sex, age and race/ethnicity 
impeded us from constructing age-, sex- and race/ethnicity-adjusted neighborhood rates. 
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Rates were smoothed using an Empirical Bayes technique to improve stability in areas with 
large populations and very few cases (Pfeiffer, 2008). Data were then mapped to the 59 
community districts using ArcMap 10.0 (ESRI, 2011). To characterize the spatio-temporal 
variation in prescription opioid overdose mortality, we used bivariate Moran’s I statistics 
and estimated the correlation between neighborhood distribution of overdose deaths in 
1990–1995 and 1996–2000, as well as between 1996–2000 and 2001–2006. Spatial statistics 
were estimated using GeoDa 1.20.
Our third objective was to compare the demographic and behavioral characteristics (e.g., 
age, sex, race/ethnicity, concurrent drug toxicology) of prescription opioid overdose vs. 
heroin overdose deaths. To this end, logistic regression was used to examine the bivariable 
and multivariable relations between each of the decedent characteristics of interest and the 
likelihood of overdose deaths caused by: (1) analgesics alone compared to heroin alone and 
(2) methadone alone compared to heroin alone. All models controlled for year of death. 
Given the low frequency of overdose fatalities in places other than residence, the places of 
residence were grouped into inside (representing “inside residence”), other inside (i.e., 
workplace, jail/prison, hospital/doctor’s office/nursing home, hotel, bar/restaurant, building), 
and outside (i.e., public transportation or car, street/lots/school yard, parks or water) for this 
analysis. Models were estimated in SAS 9.2 (SAS Institute Inc., 2002–2008).
3. Results
Analgesic and methadone overdose deaths are described in Table 1 and indicate that deaths 
were most common among middle-aged adults and males. While analgesic overdose was 
most frequent among Whites, methadone overdose was evenly distributed across Whites, 
Blacks and Hispanics. Heroin was a contributing cause in 44.6% of analgesic- and 39.9% of 
methadone-induced overdose fatalities. The majority of deaths occurred in a residence 
(82.7% of analgesic- and 79.9% of methadone-induced deaths), and deaths were evenly 
distributed across the largest NYC boroughs (Manhattan, Bronx, Brooklyn, and Queens). 
The most frequently detected non-opioid drugs were cocaine (45.7% of analgesic- and 
53.2% of methadone-induced deaths), followed by antidepressants (37.4% of analgesic- and 
37.3% of methadone-induced deaths).
3.1. Changes in epidemiologic patterns of prescription opioid overdose death
Prescription opioid deaths evolved in a distinct manner from other drugs in 1990–2006, the 
years leading to the emergence of the analgesic opioid overdose epidemic (Fig. 1). Cocaine-, 
heroin- and alcohol-induced deaths peaked in 1993–1995 with rates of 15.5/100,000, 
14.1/100,000 and 6.9/100,000, respectively. In contrast, methadone-induced deaths peaked 
in 1991 (3.2/100,000) and in 2006 (4.4/100,000), while analgesic-induced deaths increased 
steadily starting in 1999 and reached their highest rates (2.7/100,000) in 2006. Analgesic 
overdose fatalities were the only types of overdose to exhibit significantly increasing trends 
from 1990 to 2006 (Z test of trend statistic = 3.13, P < 0.01); the analgesic overdose rate 
was almost seven times higher in 2006 than in 1990. The proportion of all overdose deaths 
caused by analgesics increased from 3.9% to 15.6% while the proportion of overdose deaths 
caused by methadone overdose fatalities increased from 15.9% to 25.1% in 1990–2006.
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The increase in analgesic overdose was driven by increased rates among White and Latinos, 
particularly males (Fig. 2a). In 1990, analgesic overdose rates were 0.62 for White, 0.56 for 
Latino and 0.41/100,000 for Black males; by 2006, the rates were 6.00 for White, 3.58 for 
Latino and 2.22/100,000 for Black males. Only White and Latino males exhibited a 
significant increase in analgesic overdose from 1990 to 2006 (Z test of trend statistic = 3.54; 
P < 0.01 and Z test of trend statistic = 2.39; P < 0.05, respectively). Among females, Whites 
and Latinas also exhibited a significant increase in analgesic overdose fatalities from 1990 to 
2006 (Z test of trend statistic = 2.81; P < 0.01 and Z test of trend statistic = 2.03; P < 0.05, 
respectively). In 1990, analgesic overdose rates were 0.31 for White, 0.27 for Latino and 
0.11 for Black females; by 2006, the rates were 1.71 for White, 1.66 for Latino and 0.91 for 
Black females.
The demographic profile of methadone overdose deaths also shifted from 1990 to 2006 (Fig. 
2b). In 1990, methadone rates were 0.88 for White, 3.14 for Latino and 5.05/100,000 for 
Black males; by 2006, the rates were 7.82 for White, 6.77 for Latino and 3.68 for Black 
males. Only White males exhibited a significant increase in methadone overdose deaths in 
this period (Z test of trend statistic = 2.83; P < 0.01), while Black males exhibited a 
significant decrease in methadone overdose deaths in the same period (Z test of trend 
statistic = 2.22; P < 0.05). Among females, Whites also exhibited a significant increase in 
methadone overdose fatalities from 1990 to 2006 (Z test of trend statistic = 3.00; P < 0.01). 
In 1990, methadone overdose rates were 0.47 for White, 1.48 for Latina and 1.25 for Black 
females; by 2006, the rates were 1.96 for White, 3.16 for Latina and 2.84 for Black females.
The temporal patterns of co-occurring drugs detected differed for analgesic and methadone 
overdose fatalities. Fig. 3a and b presents the proportion of analgesic and methadone 
overdose deaths, respectively, with positive toxicology for different types of non-opioid 
substances. The types of drugs detected in cases of analgesic overdose deaths did not vary 
over time, with the exception of cannabinoids; the proportion of analgesic overdose cases 
with a positive toxicology report for cannabinoids increased over time (Z = 2.22; P = 0.03). 
In contrast, the types of drugs detected in cases of methadone overdose deaths varied over 
time: while the proportion of cases with positive toxicology for alcohol (Z = −2.37; P = 
0.02) or cocaine (Z = −2.89; P = 0.004) decreased overtime, the proportion of cases with 
positive toxicology for cannabinoids (Z = 2.06; P = 0.04), or benzodiazepines (Z = 2.5; P = 
0.01) increased overtime.
3.2. Spatial patterns of prescription opioid overdose mortality
The rates of analgesic and methadone overdose mortality followed distinct spatial patterns 
over time. As shown by the distribution of analgesic overdose mortality rates in Fig. 4, 
clustering of analgesic overdose deaths shifted in space over time. There was no correlation 
between the neighborhoods with higher rates of analgesic overdose deaths in 1990–1995 and 
1996–2000 (bivariate Moran’s I = −0.02; P = 0.48), or the neighborhoods with higher rates 
in 1996–2000 and 2001–2006 (I = −0.01; P = 0.55). In contrast, clusters of neighborhoods 
with high rates of methadone overdose surrounded by other neighborhoods with high rates 
remained stable over time (Fig. 4). There was a high and significant correlation between 
neighborhoods with higher methadone overdose death rates in 1990–1995 and 1996–2000 (I 
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= 0.45; P = 0.001), and between the spatial distribution of methadone overdose death rates 
in 1996–2000 and 2001–2006 (I = 0.43; P = 0.001).
3.3. Differences in epidemiologic patterns of prescription opioid and heroin overdose 
deaths
Prescription opioid-only overdose deaths presented different demographic and behavioral 
characteristics from heroin overdose deaths (Table 2). Relative to heroin overdose 
decedents, decedents from analgesic-only or methadone overdose-only were more likely to 
be female. Overdose fatalities induced by analgesics or methadone were less likely to occur 
outside of a residence than heroin overdose fatalities, and they were less likely to involve 
alcohol or cocaine. They were more likely to involve the use of benzodiazepines and 
antidepressants. Relative to heroin overdose decedents, analgesic overdoses were less likely 
to be experienced by Blacks or Hispanics, and they were more likely to occur in Queens or 
Staten Island. In contrast, decedents from methadone overdose were more likely to be Black 
or Hispanic and to have overdosed in Staten Island than heroin overdose decedents.
4. Discussion
The period from 1990 to 2006 was a time of significant growth in analgesic overdose 
fatalities in NYC. While methadone overdose remained stable, the rate of analgesic 
overdose deaths in NYC in 2006, at 2.7 per 100,000 persons, was almost seven times higher 
than the rate in 1990; indeed, analgesic overdose was the only type of overdose fatality to 
escalate in this period. Increased rates of analgesic overdose fatalities can be driven by 
increased rates of analgesic use and misuse, as well as by changes in the rate of mortality 
among users who overdosed. The parallel sharp increase in rates of use (Blanco et al, 2007; 
Zacny et al., 2003) and abuse/dependence (Blanco et al., 2007) in the study period suggests 
that a major contributor to the escalation in analgesic overdose mortality were the growing 
rates of analgesic use and abuse that followed the tenfold increase in the medical use of 
opioids since 1990 (Okie, 2010). In 1997–2007, per capita retail purchases of hydrocodone 
and oxycodone increased 4-fold and 9-fold, respectively (ARCOS: Automation of Reports 
and Consolidated Orders System, 2012); sales, substance abuse treatment admissions and 
overdose death rates have increased in parallel (CDC, 2011).
Due to the focused rise in analgesic opioid overdose fatalities among Whites, the gap across 
racial/ethnic groups increased over time, so that by 2006, the analgesic overdose fatality rate 
among White males was almost two times higher than the rate among Latinos and almost 
three times higher than the rate among Blacks. These inequalities are consistent with 
patterns found elsewhere: at a national level, the analgesic overdose rate among Whites was 
three times higher than rates in Blacks and Latinos (CDC, 2011); state-level studies reported 
similar findings (Piercenfield et al., 2010; Shah et al., 2008). The differences may reflect 
different patterns of drug use in the different racial/ethnic groups throughout the sixteen 
years of study. Prior studies have found that Blacks are more likely to overdose on cocaine, 
while Whites and Latinos are more likely to overdose on opioids and alcohol (Coffin et al., 
2003; Galea et al., 2003). In the case of analgesics, racial/ethnic differences in access may 
play an important role, given the same clinical presentation and report of pain level, racial/
Cerdá et al. Page 8













ethnic minorities are less likely to receive a prescription for an analgesic (Green et al., 2005; 
Mayer et al., 2008). Price may also play a role (Greenwald and Hursh, 2006); the lower 
price of heroin relative to analgesics may create an economic disincentive for racial/ethnic 
minorities to consume analgesics.
Methadone overdose fatalities also experienced a demographic shift, by 2006, the 
methadone overdose fatality rate among Whites was two times higher than the rate among 
Blacks. While methadone overdose rates among Whites increased almost nine-fold in 1990–
2006, overdose rates among Blacks decreased by 27% in the same period. Concurrently, the 
pattern of co-occurring drugs detected with methadone shifted from cocaine to cannabinoids 
and benzodiazepines. These changes may reflect the shift in the nature of methadone use, 
from a focused use as a treatment for heroin addiction, primarily among racial/ethnic 
minorities with a history of substance abuse, to increasing use as a treatment for chronic 
non-cancer pain, in conjunction with analgesics and other types of prescription drugs 
(Paulozzi et al., 2009; Paulozzi, 2012).
Analgesic and methadone overdose fatalities exhibited strikingly different spatial patterns 
over time. While clusters of analgesic overdose fatalities shifted spatially from 1990 to 
2006, methadone overdose fatalities were concentrated in the same neighborhoods from 
1990 to 2006. The distinct spatio-temporal patterns exhibited by analgesics vs. methadone 
suggest that each type of prescription opioid may also be associated with distinct contextual 
factors. To provide local context, it is worth noting that the neighborhoods with high rates of 
analgesic overdose fatalities were characterized by high income inequality but lower rates of 
poverty in the year 2000 (United States Census Bureau, 2000). In contrast, methadone 
overdose fatalities were consistently concentrated in neighborhoods with high income 
inequality, high rates of poverty and lower median income (United States Census Bureau, 
2000). Future studies need to investigate the role that contextual factors play in the 
proliferation of analgesic vs. methadone overdose fatalities over time.
Despite high rates of co-occurrence with heroin, prescription opioid overdose presents a 
different etiologic profile from heroin overdose. In our study, methadone and analgesic 
opioid decedents were less likely to present traces of alcohol or cocaine than heroin 
overdose decedents, but they were more likely to show traces of psychotherapeutic drugs 
such as benzodiazepines and antidepressants. They were also more likely to be female than 
heroin overdose decedents, and to overdose at home. Studies in other states also found that 
prescription opioid overdose decedents were more likely to be female and have co-occurring 
use of psychotherapeutic drugs (Green et al, 2011; Shah et al., 2008). These findings 
indicate that the prescription opioid consumer may be quite distinct from the heroin 
consumer, showing a lower involvement in street-based forms of drug trafficking, access 
and consumption, and less comorbid consumption of drugs such as cocaine. Given the 
increasing rates of prescription opioid overdose fatalities in urban areas such as NYC, we 
may need to develop a distinct response to this problem.
This study is subject to several limitations. First, the OCME classified certain deaths as 
caused by “unspecified opioids” and some of these cases may be methadone or analgesic 
overdose deaths, leading to an underestimate of the prevalence of prescription opioid 
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overdose in our study. Second, we had no information on the source of prescription opioids, 
i.e., whether it had been obtained from a licensed provider or from a third party. Third, data 
was only available until 2006. Subsequent trends remain to be analyzed once more recent 
data becomes accessible. However, an examination of the demographic profile of 
prescription opioid overdose fatalities in a period that experienced dramatic growth in 
prescription opioid overdose provided critical information on potential factors associated 
with the proliferation of prescription opioid abuse.
Early recognition of drug abuse patterns is critical to the design of strategies that prevent use 
and abuse from spreading and stop an epidemic before it emerges. This study provides 
insights about the emergence of an analgesic opioid epidemic in a large, multiethnic urban 
area, as well as a potentially developing methadone overdose epidemic among White 
residents who may use methadone to treat chronic pain. Our findings suggest that in order to 
prevent the development of a prescription opioid epidemic, steps in the 1990s to increase the 
availability and use of analgesics, including aggressive marketing of potent formulations 
such as oxycodone hydrochloride and efforts to encourage clinicians to be more proactive in 
identifying and treating chronic pain, should have been accompanied by stricter measures to 
regulate sales of analgesics and to prevent the proliferation of illicit high-volume prescribers 
(Boudreau et al., 2009; Paulozzi et al., 2006). At the current time, effective reduction of 
prescription opioid overdose deaths in NYC will require localized interventions, including 
real-time prescription monitoring programs, that shape availability and access to prescription 
drugs, focused action by law enforcement to identify networks of illicit distribution of 
prescription opioids, policies to increase naloxone dispensation to reduce fatalities from 
overdose, increased use of buprenorphine rather than methadone for harm reduction, and 
education of physicians and health care providers about prescription drug abuse and 
overdose (Pew Health Group, 2012).
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Standardized overdose death rates by type of drug, New York City, 1990–2006.
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(a) Analgesic-induced death rates by race/ethnicity and sex, New York City, 1990–2006. (b) 
Methadone-induced death rates by race/ethnicity and sex, New York City, 1990–2006.
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(a) Proportion of analgesic-induced overdose deaths with other drugs detected, by type of 
drug. (b) Proportion of methadone-induced overdose deaths with other drugs detected, by 
type of drug.
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Age-adjusted analgesic- and methadone-induced overdose death rates by community 
district, New York City. Maps are presented in three panels (from left to right) for the 
periods of 1990–1995, 1996–2000, and 2001–2006. Analgesic overdose fatalities are 
presented in the upper row, and methadone overdose fatalities are presented in the lower 
row.
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Table 1
Characteristics of analgesic- and methadone-induced overdose deaths, New York City, 1990–2006.a,b
Analgesic overdose Methadone overdose
N % N %
Total 681 100 2207 100
Sex
  Male 488 71.66 1522 68.96
  Female 193 28.34 685 31.04
Race/ethnicity
  White 409 60.06 808 36.61
  Black 116 17.03 679 30.77
  Hispanic 148 21.73 704 31.90
Age
  15–24 45 6.61 67 3.04
  25–34 134 19.68 347 15.72
  35–44 268 39.35 962 43.59
  45–54 190 27.90 684 30.99
  55–64 44 6.46 146 6.62
Place of injury
  Residence 532 82.74 1632 79.92
  Workplace 3 0.47 9 0.44
  Jail/prison 1 0.16 13 0.64
  Hospital/doctor’s office/nursing home 10 1.56 52 2.55
  Public transportation or car 18 2.80 57 2.79
  Hotel (in room or elsewhere) 38 5.91 88 4.31
  Bar/restaurant 4 0.62 5 0.24
  Streets/lot/school yard 24 3.73 137 6.71
  Parks or water 5 0.78 19 0.93
  Building (public, abandoned or unspecified) 8 1.24 30 1.47
  Unknown 38 5.60 165 7.50
Borough of death
  Manhattan 167 24.52 611 27.68
  Bronx 140 20.56 551 24.97
  Brooklyn 151 22.17 618 28.00
  Queens 171 25.11 336 15.22
  Staten Island 52 7.64 91 4.12
Heroin as a contributing cause
  No 377 55.36 1646 60.07
  Yes 304 44.64 1094 39.93
Drugs detected
  Alcohol detected
    No 437 64.17 1492 67.60
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Analgesic overdose Methadone overdose
N % N %
    Yes 230 33.77 664 30.09
Cannabinoids detected
    No 408 59.91 1148 52.02
    Yes 60 8.81 140 6.34
Cocaine detected
    No 370 54.33 1034 46.85
    Yes 311 45.67 1173 53.15
Benzodiazepines detected
    No 428 62.85 1667 75.53
    Yes 253 37.15 540 24.47
Antidepressants detected
    No 426 62.56 1384 62.71
    Yes 255 37.44 823 37.29
a
The two groups are not exclusive – there are overlapping cases of analgesic- and methadone-induced overdose fatalities.
b
Some frequencies do not add up to 100% due to missing data.
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